The stock of Taysha Gene Therapies Inc. (NASDAQ:TSHA) increased by $0.7 on Tuesday to at $3.08, up 29.41 percent. The last five days have seen an average of 6,028,682 shares of common stock traded. 5 times new highs were reached in the current year, with a gain of $0.67. The average number of shares traded over the last 20 days was 12,262,070, while the average volume over the last 50 days totaled 5,065,300.
TSHA stock appreciated 357.52% since last month. On 07/31/23, the company’s shares reached a one-month low of $0.65. The stock touched a high of $4.06 on 08/29/23, after rallying from a low of $0.50 in 52 weeks. The price of TSHA stock has risen by 36.28% or $0.67 this year, reaching a new high 5 times. Still, the stock price is down -24.10% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TSHA stock investors should be aware that Taysha Gene Therapies Inc. (TSHA) stock had its last reported insider trading activity 5 days ago on Aug 24. On Aug 24, Chief Financial Officer Alam Kamran sold 33,000 shares at $2.33 each. This transaction resulted in the insider making $76,890. On Aug 16, Manning Paul B added 16,466,667 shares at a price of US$0.90. After the transaction, the insider now owns 16,466,667 shares. Chief Executive Officer Nolan Sean P. had earlier bought 444,444 shares on Aug 16 for $0.90 a share. The transaction was completed for $400,000.
Financial Health
For the three months ended June 29, Taysha Gene Therapies Inc.’s quick ratio was 1.10, while its current ratio was 1.10, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $164.95 million and revenue of $2.5 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TSHA’s return on assets (ROA) during the last 12 months has been -118.10%. There was a -417.60% return on investment (ROI) in the past year.
Earnings Surprise
According to Taysha Gene Therapies Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.4 million, while revenues rose by 100.0% to $4.71 million. It was predicted that Taysha Gene Therapies Inc.’s quarterly earnings would be -$0.38, but it ended up being -$0.31, beating the consensus by -22.60%. EBITDA was -$23.04 million for the quarter. At the end of Taysha Gene Therapies Inc.’s most recent quarter ended June 29, its liabilities totaled 118.66 million, while its total debt was $60.44 million. Equity owned by shareholders amounts to $64.47 million.
Technical Picture
Here’s a quick look at Taysha Gene Therapies Inc.’s (TSHA) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 86.43%, suggesting the stock is Overbought, with a 507.52% historical volatility rate.
The stochastic %K and %D were 85.88% and 82.41% respectively, while the average true range (ATR) was 0.31. Based on the 14-day stochastic reading of 98.25%, the RSI (14) reading is 84.82%. On the 9-day MACD Oscillator, the stock is at 0.31, and the 14-day reading is at 0.55.
Analyst Ratings
Taysha Gene Therapies Inc. (NASDAQ: TSHA) was downgraded by Jefferies to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Taysha Gene Therapies Inc. (TSHA) an Buy rating. TSHA is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 7 others recommend it as a buy.
What is TSHA’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $8.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Taysha Gene Therapies Inc. (TSHA) is $5.72.
